Skip to content
Find Clinical Trials
Find Clinical Trials

Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Servier Protocol Code: CL2-18986-009 Sponsor: Institut de Recherches Internationales Servier Clinicaltrials.gov Identifier: NCT00202540 EudraCT Number: 2004-004327-35

Find a recruiting site

How to participate in this study
If you think you are eligible for this study (see
eligibility criteria
below), you can identify the location closest to you and contact them directly. If you can’t find a location close to you, please contact Institut de Recherches Internationales Servier (I.R.I.S.)
Name: Institut de Recherches Internationales Servier, Département des études cliniques
Phone number: +33 1 55 72 60 00
The study has 1 location

Study description

The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI
Official title: Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period
Results
Conditions
Mild Cognitive Impairment
Interventions / Treatments
  • S18986
Other study id numbers
  • CL2-18986-009

Eligibility Criteria

Eligible age for the study

55 years and older (Adult, Older Adult)

Sex

Male/Female

Accepts Healthy Volunteers

No

  • * Memory complaint
  • * Acetylcholinesterase inhibitors stopped at least 3 months before selection

  • * Dementia
  • * Parkinson's disease
  • * Vascular disorder
  • * Depression
  • * Epilepsy

How is the study designed?

Allocation
Randomized
Interventional study model
Parallel

Keywords

Additional Relevant MeSH Terms Glioma
Cognitive Dysfunction